- The Coulter Foundation's Wallace H. Coulter Award
for Healthcare Innovation Recognizes Excellence and Leadership in
Clinical Diagnostic Medicine -
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Veracyte,
Inc. (NASDAQ: VCYT) announced today that the company's Chairman and
CEO Bonnie Anderson is the recipient of the 2017 Wallace H. Coulter
Award for Healthcare Innovation. Dr. Lori Setton, president of the
Biomedical Engineering Society BMES, will present the award to Ms.
Anderson today at the 2017 BMES Annual Meeting in Phoenix, AZ. Ms.
Anderson will deliver a keynote lecture during a plenary session at the
meeting.
This press release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20171013005391/en/
Bonnie Anderson, Chairman and CEO, Veracyte, Inc. (Photo: Business Wire)
The Coulter Award for Healthcare Innovation recognizes excellence and
leadership in clinical diagnostic medicine, and honors the lifelong
achievements of Mr. Coulter, co-founder of the company that later became
Beckman Coulter. A committee comprising representatives from the Coulter
Foundation and BMES determine nominations and select an annual winner.
Ms. Anderson follows Medtronic Chairman and CEO Omar Ishrak, who
received the award in 2016.
"This award was created to recognize innovation in medical research and
engineering that improves healthcare," said Kevin Otto, co-chair of the
BMES Annual Meeting. "Bonnie Anderson and Veracyte embody this
innovative spirit, as well as the leadership and expertise that are
necessary to translate innovative ideas into real-world tools that have
a meaningful impact on patient outcomes."
Ms. Anderson founded Veracyte in 2008 and took the company public in
2013. With a business plan and $21 million dollars in venture capital
funding, Ms. Anderson and her world class team created a pioneering
genomic diagnostics company that is setting new standards in disease
diagnosis. In less than 10 years, Veracyte has introduced three
first-to-market commercial products that have helped tens of thousands
of patients avoid unnecessary surgery and are providing hundreds of
millions of dollars in savings to the health care system.
"I am so honored to receive this award, because it recognizes exactly
what we have worked so hard to do at Veracyte - develop innovative
diagnostic products that have a real impact on patients," Ms. Anderson
said. "I am also incredibly humbled because my 18-year career at Beckman
Coulter, where I was offered amazing opportunities to learn and lead, is
much of the reason I'm here today. The company and Mr. Coulter ignited
an entrepreneurial passion, which ultimately inspired us to create
Veracyte."
Ms. Anderson's corporate and industry leadership have been recognized
consistently over the past several years. Fast Company named her
to its list of "100 Most Creative People in Business 2015" and the San
Francisco Business Times has selected her as one of the "Bay Area's
Most Admired CEOs."
About Veracyte
Veracyte (NASDAQ: VCYT) is a leading genomic diagnostics company that is
providing trustworthy and actionable answers that fundamentally improve
patient care when current diagnostic tests are uncertain. The company's
products uniquely combine genomic technology, clinical science and
machine learning to provide answers that give physicians and patients a
clear path forward without risky, costly surgery that is often
unnecessary. Since its founding in 2008, Veracyte has commercialized
three genomic tests, which are transforming the diagnosis of thyroid
cancer, lung cancer and idiopathic pulmonary fibrosis and collectively
target a $2 billion market opportunity. Veracyte is based in South San
Francisco, California. For more information, please visit www.veracyte.com
and follow the company on Twitter (@veracyte).
Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma
logo are trademarks of Veracyte, Inc.
About the Wallace H. Coulter Foundation
Wallace H. Coulter, the benefactor of the Coulter Foundation, invented
the Coulter Principal, an electronic method of counting and classifying
microscopic particles suspended in fluid. Coulter utilized this
principal to create an apparatus known as the "Coulter Counter" that
revolutionized the practice of clinical laboratory medicine by counting
and classifying blood cells, a process that was previously done
manually. Throughout his lifetime, Coulter was a champion of practical
translational research directed to improving the scope and quality of
clinical diagnostic medicine. As a continuation of Mr. Coulter's
life-long work, the Coulter Foundation supports the discipline of
biomedical engineering at universities and medical schools. The
Foundation provides risk capital, expertise, and guidance to help
innovative initiatives realize their potential, and is guided by the
principle to address the needs of the under-served, under-resourced,
and/or under-represented.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by words such as:
"anticipate," "intend," "plan," "expect," "believe," "should," "may,"
"will" and similar references to future periods. Examples of
forward-looking statements include, among others, our belief that we are
setting new standards in disease diagnosis and the potential benefits of
the company's tests. Forward-looking statements are neither historical
facts nor assurances of future performance. Instead, they are based only
on our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, anticipated events
and trends, the economy and other future conditions. Forward-looking
statements involve risks and uncertainties, which could cause actual
results to differ materially, and reported results should not be
considered as an indication of future performance. These risks and
uncertainties include, but are not limited to: demand for our tests, the
applicability of clinical results to actual outcomes; laws and
regulations applicable to our business, including potential regulation
by the Food and Drug Administration or other regulatory bodies; our
ability to successfully achieve and maintain adoption of and
reimbursement for our products; the amount by which use of our products
are able to reduce invasive procedures and misdiagnosis, and reduce
healthcare costs; the occurrence and outcomes of clinical studies; the
timing and publication of clinical study results; and other risks set
forth in the company's filings with the Securities and Exchange
Commission, including the risks set forth in the company's Quarterly
Report on Form 10-Q for the quarter ended June 30, 2017. These
forward-looking statements speak only as of the date hereof
and Veracyte specifically disclaims any obligation to update these
forward-looking statements.
Veracyte, Percepta, and the Veracyte logo are trademarks of Veracyte,
Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171013005391/en/
Veracyte, Inc.
Media:
Tracy Morris, 650-380-4413
Tracy.Morris@Veracyte.com
or
Investors:
Jackie
Cossmon, 650-243-6371
jackie@veracyte.com
Source: Veracyte, Inc.
News Provided by Acquire Media